- Drug Pipelines
- November 2024
- 80 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Drug Pipelines
- March 2025
- 60 Pages
Global
From €1198EUR$1,250USD£1,001GBP
- Report
- November 2024
- 189 Pages
Global
From €7621EUR$7,950USD£6,368GBP
- Report
- June 2024
- 200 Pages
Global
From €7621EUR$7,950USD£6,368GBP
- Report
- June 2024
- 200 Pages
Global
From €7621EUR$7,950USD£6,368GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Report
- August 2022
- 104 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Report
- April 2022
- 55 Pages
Global
From €1917EUR$2,000USD£1,602GBP
Myositis is a type of immune disorder that affects the muscles and is characterized by muscle inflammation and weakness. Treatment for myositis typically involves a combination of medications, physical therapy, and lifestyle changes. Drugs used to treat myositis include corticosteroids, immunosuppressants, and biologics. Corticosteroids are used to reduce inflammation and pain, while immunosuppressants are used to reduce the activity of the immune system. Biologics are used to target specific proteins that are involved in the inflammation process.
The myositis drug market is a rapidly growing segment of the immune disorder drugs market. It is driven by the increasing prevalence of myositis, the development of new drugs, and the increasing demand for personalized treatments. Companies in the myositis drug market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more